Form 4: Mirum CEO Christopher Peetz Executes Stock Option Sale

Mirum Pharmaceuticals CEO Christopher Peetz exercised 30,000 stock options and sold a portion of the resulting shares under a Rule 10b5-1 trading plan.

Summary

• CEO Christopher Peetz exercised 30,000 stock options at an exercise price of $2.936 per share.
• Following the exercise, the CEO sold 30,000 shares of common stock in multiple transactions on June 1, 2026.
• The sales were executed at weighted average prices ranging from $94.64 to $99.66 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 2, 2026.
• Post-transaction, the CEO maintains direct ownership of 194,309 shares and indirect ownership of 187,500 shares via The Peetz Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine, pre-planned insider transaction that does not reflect a change in the company's fundamental outlook.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sales were not based on non-public information.
• The CEO retains a significant equity stake in the company, totaling 381,809 shares across direct and indirect holdings.

Negatives

• The sale represents a liquidation of equity by the company's top executive, which may be perceived as a signal of profit-taking.

Risks

• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market sentiment regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales via 10b5-1 plans are standard practice for liquidity and diversification, and this activity is consistent with typical executive compensation management in the biotechnology sector.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to sell shares while avoiding allegations of insider trading.
• The volume of shares sold relative to the CEO's total holdings is relatively small, suggesting a routine financial planning event rather than a lack of confidence in the company.

Related Party Transactions

• The reporting person holds 187,500 shares indirectly through The Peetz Family Trust.

Stakeholder Impact

• Minimal impact expected as the sales were pre-planned and represent a small portion of the CEO's total beneficial ownership.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Insider Trading, Form 4, Christopher Peetz, Stock Options